Exagen
Biotechnology · 200 employees
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® C
Funding history
- Funding Round — $35.0M — Aug 2022
- Funding Round — $6.6M — Feb 2019
- Series seed — $3.7M — May 2017
- Series seed — $1.3M — Apr 2017
- Series seed — $1.5M — Mar 2017
Recent signals
- Jun 09, 2026: SEC 8-K (5.02): On June 9, 2026, Exagen Inc. held its 2026 annual meeting of stockholders where two Class I directors were elected for a three-year term. The elected directors are Tina S. Nova, Ph.D., who received 8,094,349 votes for and 220,954 withheld, and Scott Kahn, Ph.D., who garnered 6,295,837 votes for and 2,019,466 withheld. This annual meeting is significant as it shapes the board's direction and governance, impacting future strategic decisions and company performance. The votes reflect stockholder confidence in the selected candidates and their strategic vision for Exagen Inc.
- Jun 23, 2025: Exagen Appoints Dr. Michael Mahler as Chief Scientific Officer
- Nov 14, 2024: Launched Exagen Inc. announces new biomarkers for lupus and rheumatoid arthritis on the AVISE CTD platform to enhance autoimmune diagnostic testing.
- Aug 25, 2022: Raised $35.0M
- Feb 01, 2019: Raised $6.6M
- May 18, 2017: Raised $3.7M in Series seed
- Apr 10, 2017: Raised $1.3M in Series seed
- Mar 09, 2017: Raised $1.5M in Series seed
See plans & pricing → Track Exagen’s funding, hiring, and signals — with verified contacts — on Fundz.